Phase I/II study of docetaxel and OSI-774 (erlotinib) in solid tumor patients with an emphasis on NSCLC [non-small cell lung cancer] using molecular correlates as potential markers of response.
Phase of Trial: Phase I/II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 27 Mar 2012 Companies (Genentech, Aventis Pharmaceuticals) added as trial sponsor as reported by ClinicalTrials.gov.
- 06 Apr 2010 Additional lead trial centre (National Cancer Institute) and lead trial investigator (Gandara DR) added as reported by ClinicalTrials.gov record.